Therapeutic Cytapheresis, Plasmapheresis, and Plasma Exchange in Neoplastic Diseases of the Blood

2012 ◽  
pp. 1241-1249 ◽  
Author(s):  
Janice P. Dutcher
The Lancet ◽  
1980 ◽  
Vol 315 (8167) ◽  
pp. 688-689
Keyword(s):  

2013 ◽  
Vol 44 (02) ◽  
Author(s):  
S Bigi ◽  
B Banwell ◽  
EA Yeh

Author(s):  
Gürkan Atay ◽  
Demet Demirkol

AbstractTherapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases. In this study, we aimed to assess the indications, efficacy, reliability, complications, and treatment response of pediatric patients for TPE. This retrospective study analyzed data from 39 patients aged from 0 to 18 years who underwent a total of 172 TPE sessions from January 2015 to April 2018 in a tertiary pediatric intensive care unit. Indications for TPE were, in order of frequency, macrophage activation syndrome (28.2%, n = 11), renal transplantation rejection (15.4%, n = 6), liver failure (15.4%, n = 6), Guillain–Barre's syndrome (15%, n = 6), hemolytic uremic syndrome (7.7%, n = 3), acute demyelinating disease (7.7%, n = 3), septic shock (5.1%, n = 2), and intoxication (5.1%, n = 2). No patient had any adverse event related to the TPE during the procedure. The TPE session was ended prematurely in one patient due to insufficient vascular access and lack of blood flow (2.6%). In the long term, thrombosis due to the indwelling central catheter occurred (5.1%, n = 2). TPE appears to be an effective first-stage or supplementary treatment in a variety of diseases, may be safely used in pediatric patients, and there are significant findings that its area of use will increase. In experienced hands and when assessed carefully, it appears that the rate of adverse reactions and vascular access problems may be low enough to be negligible.


2016 ◽  
Vol 4 (1) ◽  
pp. 9 ◽  
Author(s):  
Aneta Tomescu ◽  
Rodica Sîrbu ◽  
Stelian Paris ◽  
Emin Cadar ◽  
Cristina Luiza Erimia ◽  
...  

Our study is a rewiew of Methotrexate therapy in obstetrica? diseases such us: hydatidiform mole, and medical abortion. In the medical world, methotrexate is a citostatic drug used in neoplastic diseases. The clinical pharmacology data regarding methotrexate is presented, alongside route of administration and therapeutic effects in malignant disease, hydatiform mole, and medical abortion. The use of methotrexate in medical abortion and ectopic pregnancy is a great accomplishment, as it replaces a surgical intervention marred by characteristic side effects, with similar results.


2016 ◽  
Vol 2 (1) ◽  
pp. 9 ◽  
Author(s):  
Aneta Tomescu ◽  
Rodica Sîrbu ◽  
Stelian Paris ◽  
Emin Cadar ◽  
Cristina Luiza Erimia ◽  
...  

Our study is a rewiew of Methotrexate therapy in obstetrica? diseases such us: hydatidiform mole, and medical abortion. In the medical world, methotrexate is a citostatic drug used in neoplastic diseases. The clinical pharmacology data regarding methotrexate is presented, alongside route of administration and therapeutic effects in malignant disease, hydatiform mole, and medical abortion. The use of methotrexate in medical abortion and ectopic pregnancy is a great accomplishment, as it replaces a surgical intervention marred by characteristic side effects, with similar results.


2018 ◽  
Vol 20 (4) ◽  
pp. 394-403
Author(s):  
M. S. Vetsheva ◽  
◽  
K.E Loss . ◽  
O.L. Podkorytova ◽  
E.V. Lebedkov ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document